Aqueous Humor and Ocular Tissue Analysis in Glaucoma and Cataract (NCT07462000) | Clinical Trial Compass
RecruitingNot Applicable
Aqueous Humor and Ocular Tissue Analysis in Glaucoma and Cataract
Poland40 participantsStarted 2026-01-21
Plain-language summary
This observational study will compare proteomic and elemental profiles of aqueous humor and ocular tissues in patients with primary open-angle glaucoma (POAG) and cataract versus cataract controls without glaucoma. Samples collected during standard surgery will be analyzed using LC-MS/MS and ICP-MS. The goal is to identify glaucoma-associated molecular patterns with potential diagnostic or prognostic relevance.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age ≥ 18 years.
* Scheduled for cataract surgery (phacoemulsification with intraocular lens implantation).
* Ability to provide written informed consent.
* For glaucoma arm: diagnosis of primary open-angle glaucoma (POAG) with coexisting cataract, and planned combined cataract surgery with glaucoma procedure.
* For control arm: cataract without glaucoma and without other significant ocular pathology.
Exclusion Criteria:
* Age \< 18 years.
* Pregnancy or breastfeeding.
* Advanced visual impairment in the study eye (visual aquity worse than counting fingers).
* Any glaucoma type other than primary open-angle glaucoma (e.g., angle-closure, secondary, neovascular glaucoma).
* History of intraocular surgery in the study eye (including glaucoma surgery), vitreoretinal surgery, corneal transplantation, or refractive surgery.
* Active or previous uveitis.
* Other significant chronic ocular disease in the study eye (other than cataract and POAG in the glaucoma arm).
* Inability to comply with study procedures or follow-up visits.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
IOP
Timeframe: Through study completion, an average of 1 year
2
Visual Field
Timeframe: Through study completion, an average of 1 year
3
BCVA
Timeframe: Through study completion, an average of 1 year
4
Protein expression
Timeframe: Through study completion, an average of 1 year
5
RNFL
Timeframe: Through study completion, an average of 1 year
Trial details
NCT IDNCT07462000
SponsorMilitary Institute od Medicine National Research Institute